XELJANZ 11 mg prolonged-release tablets
ChronIA001
Approved small_molecule active
Quick answer
XELJANZ 11 mg prolonged-release tablets for Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria
- Phase
- Approved
- Modality
- small_molecule
- Status
- active